Viewing Study NCT03391193


Ignite Creation Date: 2025-12-25 @ 1:16 AM
Ignite Modification Date: 2026-01-01 @ 9:21 AM
Study NCT ID: NCT03391193
Status: COMPLETED
Last Update Posted: 2022-04-25
First Post: 2017-12-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine
Sponsor: Sanofi Pasteur, a Sanofi Company
Organization:

Study Overview

Official Title: Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 Months to 17 Years
Status: COMPLETED
Status Verified Date: 2022-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of the study is to to assess the immunogenicity and safety of a quadrivalent influenza vaccine in a multi-dose presentation compared to a quadrivalent influenza vaccine in single-dose presentation, in children aged 6 months to 17 years.
Detailed Description: Participants aged 9 to 17 years will receive one dose of either the multi-dose quadrivalent influenza vaccine or the quadrivalent influenza vaccine in a single-dose presentation and participants aged 6 months to 8 years will receive 2 doses of either vaccine, 28 days apart.

All participants will provide a pre-vaccination blood sample on Day 0 and a post-vaccination blood sample either on Day 28 (participants aged 9 to 17 years) or on Day 56 (participants aged 6 months to 8 years) for immunogenicity testing.

All participants will be followed for safety evaluation up to 6 months after the last vaccination.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: